PMID- 11528553
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20151119
IS  - 0300-8630 (Print)
IS  - 0300-8630 (Linking)
VI  - 213
IP  - 4
DP  - 2001 Jul-Aug
TI  - [Expression of the neurotrophin-receptor TrkB predicts outcome in 
      nephroblastomas: results of a pilot-study].
PG  - 191-6
AB  - BACKGROUND: The neurotrophin-receptor TrkB plays an important role in 
      pathogenesis, biology and prognosis of neuroblastoma. Expression of TrkB on 
      aggressive neuroblastomas leads to proliferation and survival of the tumor cells 
      and is associated with an unfavorable prognosis. It is now known that Trk 
      receptors are also expressed in extraneural tissues including the kidney. 
      PATIENTS AND METHODS: To study the role of the neurotrophin-receptor TrkB in 
      nephroblastoma/Wilms' Tumor (WT), we determined TrkB mRNA expression by 
      semiquantitative duplex RT-PCR in 39 primary WT. Comparison of mRNA expression 
      levels with clinical variables was performed using Cox regression analysis. 
      RESULTS: The 5-year overall survival was significantly worse for patients with 
      tumors expressing high levels of a functional TrkB-receptor (TrkBfull) in 
      comparison to patients with low levels of TrkBfull (70 % versus 100 %, p=0.005). 
      Conversely, children with tumors expressing high mRNA levels of a functionally 
      inactive truncated TrkB receptor (TrkBtrunc) had a significantly higher 5-year 
      overall survival rate in comparison to patients with low levels of TrkBtrunc (100 
      % versus 68 %, p=0.003). The hazard ratios for TrkBfull and TrkBtrunc remained 
      significant after adjusting for tumor stage. All WT with high levels of TrkB also 
      expressed the ligand brain-derived neurotrophic factor (BDNF). CONCLUSIONS: 
      Full-length and truncated TrkB appear to be important prognostic factors in WT. 
      Their expression should be assessed prospectively in a larger panel of WT and may 
      have a future role in patient assignment to risk-based treatment strategies. TrkB 
      signaling may be reduced in WT with favorable outcome due to low numbers of TrkB 
      receptors or a competitive effect of functionally inactive TrkBtrunc.
FAU - Eggert, A
AU  - Eggert A
AD  - Universitatskinderklinik Essen, Abteilung fur Hamatologie/Onkologie, Germany. 
      angelika.eggert@uni-essen.de
FAU - Grotzer, M A
AU  - Grotzer MA
FAU - Zhao, H
AU  - Zhao H
FAU - Brodeur, G M
AU  - Brodeur GM
FAU - Evans, A E
AU  - Evans AE
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Die Expression des Neurotrophin-Rezeptors TrkB beeinflusst die Prognose von 
      Nephroblastomen: Ergebnisse einer Pilotstudie.
PL  - Germany
TA  - Klin Padiatr
JT  - Klinische Padiatrie
JID - 0326144
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (Receptor, trkA)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - EC 2.7.10.1 (Receptor, trkC)
SB  - IM
MH  - Adolescent
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Vitro Techniques
MH  - Infant
MH  - Kidney Neoplasms/*diagnosis/metabolism/pathology/therapy
MH  - Male
MH  - Nerve Growth Factors/genetics/*metabolism
MH  - Pilot Projects
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - RNA, Messenger/metabolism
MH  - Receptor, trkA/metabolism
MH  - Receptor, trkB/*metabolism
MH  - Receptor, trkC/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Risk
MH  - Survival Analysis
MH  - Wilms Tumor/*diagnosis/metabolism/pathology/therapy
EDAT- 2001/08/31 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/31 10:00
PHST- 2001/08/31 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/31 10:00 [entrez]
AID - 10.1055/s-2001-16858 [doi]
PST - ppublish
SO  - Klin Padiatr. 2001 Jul-Aug;213(4):191-6. doi: 10.1055/s-2001-16858.